CD274 and salivary gland cancer: Hanno et al. concluded in their paper that using established scoring criteria for PD-L1 expression (combined positivity score (CPS) and immune cell (IC) score, tumor proportion score TPS), they were able to identify which types of adenocarcinomas, not otherwise specified (AC, NOS) among malignant salivary gland tumors would benefit most from immune checkpoint inhibition [27].